Analysts' Views on MannKind's Fair Value Estimate and Future Prospects

MannKind's fair value estimate is US$7.50, with analysts clustering in the mid single digit to low double digit range. Recent commentary weighs Tyvaso DPI royalty risk against Afrezza, Furoscix, and the broader pipeline. Analysts have mixed views, with some seeing potential for the stock to reflect contributions from Furoscix and Afrezza, while others flag the challenge of disproving the bear case around potential franchise migration from Tyvaso DPI to a soft mist device.